
    
      SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses
      neurochemical and psychopharmacologic features that suggest it could improve memory and
      cognition in humans. The primary objective of the SGS742 clinical trial will be to determine
      the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate
      Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
    
  